Pepticom Project ID : 26-2014-3056
Summary of the technology
Project ID : 26-2014-3056
Computing Smart Peptides
Pepticom Ltd. is an Israeli innovative computational drug discovery company founded on December 2011, privately co-owned by the Hebrew University of Jerusalem, seed investors and the scientific team that developed Pepticom's unique technology (out of Prof. Amiram Goldblum's lab). We developed an exceptional computational software, which allows for the ab-initio design of peptides that bind a target protein. These peptides can primarily serve for drug development as protein activity modulators (agonist/antagonist). The software requires only the solved structure of a target protein for designing the peptides in three-dimensional space and provides their binding modes and calculated binding energy. The peptides undergo a complex design process, until eventually converging on to a diversified peptide library of optimal binding affinity, size and solubility
To date we have launched several research projects aimed at the discovery of innovative peptides and small-molecule drug candidates for cancer, immunology, cardiovascular and central nervous system diseases (including two EUREKA label projects). Development programs are carried out either in-house or in collaboration with a network of leading universities, biotech companies, and CROs. As our programs gain momentum and are to reach preclinical development within the next year, we are open to mutually beneficial partnering opportunities and capital investments.
Pepticom intends to become an important player in the pharmaceutical and related industry by employing our technology to shorten the time and decrease the costs of drug discovery.
We have discovered several promising active peptides in the following projects:
•A EUREKA label project aiming to find a wide array of Toll-Like Receptor (TLR) modulating peptides. Wide range of agonists and antagonists discovered, with potential usage in
•A EUREKA label project focused on novel
Alzheimer’s diseasetreatment, peptides and small molecules discovered.
•Development of inhibitors for
PCSK9-LDLrinteraction intended for hypercholesterolemia treatment.
•Innovative approach for new generation
diabetes type IItherapeutics.
Orphan diseases focus:Adult Polyglucosan Body Disease, revolutionary peptide developed for stabilizing of mutant GBE1.
•We have over 60 solved peptide libraries for various targets.
Seeking to partner with:
We have the ability of dramatically reducing time and costs relate to peptide drug discovery. We are interested in new partnerships with pharmaceutical companies and academic institutions.
The Hebrew University
Dr. Maayan Elias, B.D.O., e-mail:firstname.lastname@example.orgMob: +972(0)54-9554990
VP Business Development Healthcare
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research
Technology Transfer Office from IsraelYissum - Research Development Company of the Hebrew University
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.